Sunesis
Navigation Links
Sunesis in Medical News
NEW YORK, Sept. 17 /PRNewswire/ -- ExL Pharma is pleased to announce
three Clinical Data Focused conferences which cover many of the leading
issues that are impacting the pharmaceutical industry today. These events
offer educational and networking opportunities for Clinical, R&D,
Regulatory an...
...RANCISCO, Calif., May 26 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar... Additionally at the ASCO 2009 Annual Meeting, sunesis will be presenting clinical data on SNS-314, a nov...ll of these presentations will be available on the sunesis website at www.sunesis.com on the same day eac...
...such as Cephalon, Inc. [CEPH], Genentech, Inc. [DNA], Infinity Pharmaceuticals, Inc. [INFI], Memory Pharmaceuticals Corp., Pharmos Corporation [PARS], sunesis Pharmaceuticals, Inc. [SNSS] and Vertex Pharmaceuticals Incorporated [VRTX]. At this point, we believe that the Company's only legitimate option ...
...ncer where topoisomerase II poisons are active." sunesis researchers conducted in vitro and cell-based stud...ancer. In a third set of studies reported today, sunesis researchers profiled the potential relationship be...sed previously in the treatment of cancer. About sunesis Pharmaceuticals ...
Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
...ANCISCO, Calif., July 27 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...ent. "We are pleased to have Helen join the sunesis Board of Directors," said Daniel Swisher, Sunesis'... track record and commercial insights will benefit sunesis significantly." Ms. Kim is currently a Dire...Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
...ANCISCO, Calif., July 13 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar... term of this collaboration ended in June of 2008. sunesis retains an option to participate in the co-develop...tor resulting from this collaboration. About sunesis Pharmaceuticals ......RANCISCO, Calif., May 26 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar... Additionally at the ASCO 2009 Annual Meeting, sunesis will be presenting clinical data on SNS-314, a nov...ll of these presentations will be available on the sunesis website at www.sunesis.com on the same day eac...
Sunesis Reports Financial Results for the First Quarter 2009
...FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today repo... Recent Highlights In April, sunesis announced the execution of a securities purchase a...acement, among other conditions. In April, sunesis presented data on voreloxin at the American Associ...Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
...ANCISCO, Calif., April 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...ate placement, and which is subject to approval by sunesis Pharmaceuticals' stockholders and the satisfaction...chievement of a specific milestone with respect to sunesis Pharmaceuticals' voreloxin product candidate and......such as Cephalon, Inc. [CEPH], Genentech, Inc. [DNA], Infinity Pharmaceuticals, Inc. [INFI], Memory Pharmaceuticals Corp., Pharmos Corporation [PARS], sunesis Pharmaceuticals, Inc. [SNSS] and Vertex Pharmaceuticals Incorporated [VRTX]. At this point, we believe that the Company's only legitimate option ...
Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
...cess a webcast of the presentation by visiting the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About sunesis Pharmaceuticals ...Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
...cess a webcast of the presentation by visiting the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About sunesis Pharmaceuticals ......ncer where topoisomerase II poisons are active." sunesis researchers conducted in vitro and cell-based stud...ancer. In a third set of studies reported today, sunesis researchers profiled the potential relationship be...sed previously in the treatment of cancer. About sunesis Pharmaceuticals ...
Sunesis in Medical Technology
SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of ...... SAN FRANCISCO , Dec. 7 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...erated. Conference Call Information sunesis management will host a conference call on Tuesday,...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
...NCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...60 Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be......SH," said Daniel Swisher, Chief Executive Officer, sunesis Pharmaceuticals. "Our goal is to advance voreloxin...been escalated to 75 mg/m2 dosed every four weeks. sunesis expects to complete enrollment of the 75 mg/m2 coh...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals ...
...n an acute need for new treatment options. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...or the treatment of solid and hematologic cancers. sunesis has built a highly experienced cancer drug develop...
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
... In conjunction with this strategic restructuring, sunesis expanded the company's late-stage development lead...tently well tolerated in multiple clinical trials. sunesis is currently conducting Phase 2 clinical trials of...nation with cytarabine for the treatment of AML. sunesis continues ongoing trials in its earlier-stage clin......ofile demonstrated in this Phase 2 clinical trial, sunesis increased the dose of voreloxin in this trial to 6...een observed. Based on voreloxin's safety profile, sunesis recently announced that the protocol for the ongoi...25 percent to 75 mg/m(2) given once every 28 days. sunesis expects to enroll approximately 30 patients at thi...
...will be available following each conference on the sunesis corporate website at http://www.sunesis.com . About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...al in patients with advanced solid tumors. About sunesis Pharmaceuticals ...
...a from this trial indicate clear clinical benefit, sunesis could initiate a pivotal trial in this highly unde...medical conference toward the end of this year." sunesis previously reported promising results from its Pha...lerated weekly dose of 72 mg/m2 was established. sunesis also announced today that voreloxin has been accep...
...by the MMRC Validation Team, in collaboration with sunesis scientists, of SNS-032 in human myeloma cell lines...cell lymphoma cell lines" (Abstract #756). About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...
Sunesis in Biological Technology
Sunesis Receives Approval for Listing on The NASDAQ Capital Market
...ANCISCO, Calif., July 30 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...ve at the opening of the market on August 3, 2009. sunesis will continue to trade under the symbol "SNSS." ...adhere to NASDAQ's corporate governance standards. sunesis requested the transfer of its listing based upon t...Sunesis Reports Financial Results for the Second Quarter 2009
...ANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today repo... Recent Highlights In April, sunesis completed a $10.0 million initial closing of a tra...$8.8 million. The remaining units may be issued by sunesis upon the satisfaction of a clinical milestone and ...Sunesis to Present at the Jefferies 3rd Annual Healthcare Conference
...ANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...cast of this presentation will be available on the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About...Sunesis Pharmaceuticals Receives NASDAQ Notification
...NCISCO, Calif., April 17 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) reported t... by the Panel following the hearing. About sunesis Pharmaceuticals sunesis is a biopharmaceutical company focused on the deve...Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
...ANCISCO, Calif., April 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today repo...s totaled $10.6 million, with no outstanding debt. sunesis Pharmaceuticals separately announced today the exe...d at all three dose levels. In March 2009, sunesis sold to SARcode Corporation all of the company's i...Sunesis to Present at the 11th Annual BIO CEO & Investor Conference
...f the Sunesis website for two weeks. About sunesis Pharmaceuticals sunesis is a biopharmaceutical company focused on the deve...or the treatment of solid and hematologic cancers. sunesis has built a highly experienced cancer drug develop...Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
...ANCISCO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today prov...eloxin study in AML by the end of this year." sunesis is providing an update on the progress of its vore...Phase 2 and 1b/2 Studies of Voreloxin in AML sunesis is evaluating single agent voreloxin in an ongoing...Sunesis to Present at Upcoming Conferences
...UTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...st of these presentations will be available on the sunesis website at http://ir.sunesis.com . A replay of t...ts" page in the Investors and Media section of the sunesis website for two weeks. About...Sunesis to Present at Upcoming Conferences
...w and Lazard Capital presentations by visiting the sunesis website at http://ir.sunesis.com . A replay of th...tion of the Sunesis website for two weeks. About sunesis Pharmaceuticals sunesis is a biopharmaceutical company focused on the deve...Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
...cess a webcast of the presentation by visiting the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About sunesis Pharmaceuticals ...Other TagssectorsectorsectorcannotCATICATICATICATICATICATICATICATIcollegesOther Contentsjointjointjointjointjointjointjointjointkaryotypekeratinkeratinkeratinkidneykidneykidneykidneykidneykidneykidneykidneykidneykinesiologykinetickinetickinetickinetickineticacidacidacidacidacidacidacidacidacidacid
(Date:12/1/2009)... , SMITHFIELD, R.I., Dec. 1 ...ve equipment, bad assumptions are hazardous and ca...ars of government regulation, a handful of persist...both the effectiveness of occupational Hearing Co... ,, A new free, white paper from Howard Leight...
(Date:12/1/2009)... , ,, NEW YORK, Dec. 1 /PRNe... a global leader in the development and delivery o... the medical, scientific and academic markets, wil...sal Search, our first-to-market cross-platform sea...hology lexicon, based on the American Psychologica...
(Date:12/1/2009)... , WASHINGTON, Dec. 1 /PRNewswire-USNewswire/ ...ncy for International Development: ,, Chairman ...mmittee. ,, I am honored to be nominated by Pre...ed States Agency for International Development, an...ency. ,, Secretary of State Clinton has expres...
(Date:12/1/2009)... , The Patient Safety Authority Encourages Ol...d and Offers New Consumer Tips Based Upon Authorit...-USNewswire/ -- Ninety percent of all vaccine prev...ing residents in nursing homes, according to highl...Authority,s 2009 December Patient Safety Advisory...
(Date:12/1/2009)...rcelona, 30 November 2009. Performing surgical op...chimera and has become a reality. This is demonstr...TES (Natural Orifice Transluminal Endoscopy Surger...rgical access using the body,s natural orifices. T...ack of scars, shorter hospital stay and faster rec...
Breaking Medicine News(10 mins):Health News:New White Paper Details Six Common Bad Assumptions About Hearing Protection 2Health News:New White Paper Details Six Common Bad Assumptions About Hearing Protection 3Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 2Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 4Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 5Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 6Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 7Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 8Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 9Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 2Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 3Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 4Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 5Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 2Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 3[0] New White Paper Details Six Common Bad Assumptions About Hearing Protection[0] Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference[0] Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009[0] Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory[0] Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus
(Date:11/30/2009)...Two so-called invasion proteins are crucial for in...face of human cells, which stimulates the host cel...r molecules exert a different function, for exampl... The group,s results have now been published in th...ogy ". , Spoiled meat is one of the sources for ...
(Date:11/30/2009)...A new research report published in the December 20...y give men similar type of control over their fert...because scientists have found how and where androg... sperm production and male fertility. This opens a..." for men. The discovery also offers hope to those...
(Date:11/26/2009)...Ecologists have at last worked out a way of using ...ize of bird populations. This is the first time so...ranslated into accurate estimates of bird species,...in the British Ecological Society,s Journal of Ap... could lead to a major advance in our ability to m...
Breaking Biology News(10 mins):It takes 2 to infect 2Ecologists sound out new solution for monitoring cryptic species 2Vivakor Presents at Nutraceutical Event 61275 1Vivakor Presents at Nutraceutical Event 61275 2Vivakor Presents at Nutraceutical Event 61275 3Vivakor Presents at Nutraceutical Event 61275 4Vivakor Presents at Nutraceutical Event 61275 5Vivakor Presents at Nutraceutical Event 61275 6Pregis Announces Third Quarter 2009 Financial Results 61271 1Pregis Announces Third Quarter 2009 Financial Results 61271 2Pregis Announces Third Quarter 2009 Financial Results 61271 3Pregis Announces Third Quarter 2009 Financial Results 61271 4Pregis Announces Third Quarter 2009 Financial Results 61271 5Pregis Announces Third Quarter 2009 Financial Results 61271 6Pregis Announces Third Quarter 2009 Financial Results 61271 7Pregis Announces Third Quarter 2009 Financial Results 61271 8Pregis Announces Third Quarter 2009 Financial Results 61271 9Pregis Announces Third Quarter 2009 Financial Results 61271 10Pregis Announces Third Quarter 2009 Financial Results 61271 11Pregis Announces Third Quarter 2009 Financial Results 61271 12Pregis Announces Third Quarter 2009 Financial Results 61271 13Pregis Announces Third Quarter 2009 Financial Results 61271 14Pregis Announces Third Quarter 2009 Financial Results 61271 15Pregis Announces Third Quarter 2009 Financial Results 61271 16AvidBiotics Corp Granted Key U S and European Patents on Unique Protein Modification Platform 14820 1AvidBiotics Corp Granted Key U S and European Patents on Unique Protein Modification Platform 14820 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |